Tevogen (TVGN) announced the signing of a letter of intent to lease a 17,428-square-foot facility in New Jersey. The facility should support the Company’s cell therapy manufacturing operations. “Our continued investment in infrastructure reflects our commitment to delivering innovative and accessible T cell therapies,” said Dr. Ryan Saadi, CEO of Tevogen Bio. “This facility has potential to efficiently scale our manufacturing as we advance our pipeline toward commercialization and will serve as a bridge as we enter the early stages of developing our own custom-built manufacturing facility.”
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TVGN:
- AI Daily: OpenAI said to end acquisition talks with Windsurf
- Tevogen.AI builds alpha version of PredicTcell model
- Tevogen Bio Grants Restricted Stock to CEO
- Tevogen Bio Holdings Enters $50M Sales Agreement
- Tevogen Bio CEO Contributes $500K for New HQ